We read with interest the paper by Walewska et al. 1 titled 'Male preponderance in chronic lymphocytic leukemia utilizing IGHV1-69'. The authors analyzed a large cohort of 1239 chronic lymphocytic leukemia (CLL) cases, comprising three patient series from different institutions in the United Kingdom. The paper confirms the well-established overall male preponderance in CLL (male/female ratio 2.1:1) while also reporting a novel potential association between male gender and usage of specific IGHV genes. They show a further increased male preponderance in the subgroup of cases utilizing IGHV1-69 (ratio 4.75: 1) , in which the number of cases analyzed (a total of 161) allowed the results to reach statistical significance. A similar trend was also suggested in IGHV1-18-expressing patients, in whom a striking male/female ratio of 14:1 was seen, but statistical significance was not reached owing to small sample size.
We undertook a similar analysis in a larger cohort consisting of 1902 unselected CLL patients, from France, Greece, Italy and Sweden, all with available sequence data on IGHV gene usage. 2, 3 Our analysis confirmed a male predominance among all CLL patients with an overall male to female ratio of 1.86:1 (ranging from 1.62 to 2.05 in the different national cohorts), which is similar to the ratio reported in the correspondence by Walewska et al.
1
That notwithstanding, when we considered the gender distribution with regard to IGHV gene usage, a different picture emerged. In particular, in our series, there were 237 cases utilizing the IGHV1-69 gene, including 174 males and 63 females, thereby leading to a male to female ratio of 2.75:1, significantly lower and more similar to normal than the one reported by Walewska et al. 1 Interestingly, if one considers the different national series from our study individually, a wide distribution of male to female ratios was evident for cases utilizing the IGHV1-69 gene, ranging from 2.20 in Italy up to 3.72 in France. This is likely due to the small sample size, as a more limited number of IGHV1-69-utilizing cases are present in each national cohort, making the differences likely due to chance rather than to an actual phenomenon.
These findings suggest caution when interpreting data obtained in subgroups of patients and strongly prompt for analysis of larger cohorts to eliminate the possibility that an observation may be simply due to chance. This is exemplified by the case of the IGHV1-18 gene. Walewska et al. suggest a striking male preponderance of 14:1, although not statistically significant owing to low number of cases. In our series, which comprised a total of 26 IGHV1-18 utilizing cases (19 males and 7 females), a lower male to female ratio (2.7:1) was apparent and was closer to that observed for the whole cohort.
On the other hand, as shown in Figure 1 , a male to female ratio below 1.5 could be observed for five IGHV genes (IGHV1-2, IGHV3-7, IGHV3-23, IGHV3-33 and IGHV4-34). Our series also showed clear differences when comparing national versus global cohort. A striking example is the IGHV3-48 gene, where the male to female ratio was 9.0 and 4.2 in the Swedish and French series respectively, while it was 2.9 for the entire group. On the basis of this evidence, it is important to recall that relatively small numbers of patients can create strong statistical biases, although these differences may also be interpreted as due to potential geographical differences.
Nevertheless, other selection biases first need to be considered and eliminated. Case selection biases are present in the British cohort: they are mainly evident in the CLL4 clinical trial cohort, which is also the predominant one as it comprises 44% of all patients. 1 In this cohort, only patients requiring therapy were enrolled. In general, males with CLL tend to have a more aggressive disease, regardless of any other clinical or biological feature, and this may lead to related gender bias.
Another important issue to take into consideration is the notion of 'stereotyped receptors', which may be more relevant than the single IGHV gene usage when analyzing any biological or clinical features, since they point out to specific antigenic stimulations. It is true that, as Walewska et al. 
Figure 1
Male to female (M:F) ratios in CLL cases from our series utilizing different IGHV genes. M:F ratios are provided for the 10 most frequent genes, which comprised from 237 cases (IGHV1-69) to 68 cases (IGHV3-33) and for the whole cohort ('all genes'). Overall and national ratios are shown with different bars.
Letters to the Editor IGHV1-69 gene can be involved in different stereotyped receptors. 3, 5, 6 We and others have reported the existence of at least eight major subsets, all utilizing the IGHV1-69 gene but leading to the production of completely different stereotyped receptors. 3, 5, 6 This suggests the existence of specific but still different antigenic elements involved in the stimulation of the leukemic clones. For this reason, the suggestion made by Walewska et al.
1 that a potential male preponderance in IGHV1-69-utilizing cases might indicate the existence of a potential autoantigen encoded on the sex chromosome becomes rather questionable. Along the same line of reasoning, we have previously provided evidence that even within the group of patients utilizing unmutated IGHV1-69 genes, the clinical prognosis may differ significantly depending on the type of IGHV1-69 stereotyped receptor, suggesting that a different binding site (that is, different antigenic elements) may be critical in shaping the clinical presentation and outcome. 3 Furthermore, it has been previously reported that a particular gender predominance may indeed be present in subsets of CLL patients carrying specific stereotyped receptors. This has been demonstrated in particular for IGHV4-39 gene-expressing cases, 7 where a female predominance is evident. In addition, although the numbers are admittedly small, a different male to female distribution may also be suggested in two IGHV1-69 stereotyped subsets from our series:
3 in particular, the first subset ('subset no. 3') comprised six males and three females whereas the second subset ('subset no. 5') comprised eight males and one female. Notably, IGHV1-69 patients of the second subset although unmutated (similar to the majority of IGHV1-69 cases) were reported to follow a strikingly indolent course.
A further critical issue that confounds analysis at the level of individual genes is that different IGHV genesFalthough belonging to the same phylogenetic clan (for example, IGHV1, IGHV5 and IGHV7)Fmay show high overall similarity and lead to the production of closely similar IGHV-D-J rearrangements and HCDR3 sequences. 3 This observation underscores the fact that caution is necessary in interpreting biological and clinical features at the individual IGHV gene level.
Again, one should remember that, given the limited number of cases available so far for each patient subset, the possibility of misinterpretation due to a small sample size cannot be ruled out. Studies in large international cohorts of CLL subsets are now needed to address these and other aspects before definitive conclusions can be reached.
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation Disease relapse is the most important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with acute myelogenous leukemia (AML) and highrisk myelodysplastic syndrome (MDS). 1 The risk of relapse is a function of several factors such as karyotype, disease status, preparative regimen intensity and the development of graftversus-host disease (GVHD). The optimal therapy for recurrence is yet to be determined with most approaches eliciting dismal results. Chemotherapy and donor lymphocyte infusion (DLI) either alone or in combination, or second transplants have been used with different degrees of success. 2, 3 Most studies describing outcomes after disease relapse in the context of reduced intensity conditioning (RIC) allogeneic transplantation involved heterogeneous groups of patients with small sample sizes. It is unclear to what extent patient selection explains the success or failure of salvage strategies. Here, we describe the outcomes of patients with AML and MDS relapsing after their first allogeneic HSCT (HSCT1) with reduced intensity or non-ablative preparative regimens. All patients were treated at the M D Anderson Cancer Center between June 1995 and
